#POLB Poolbeg Pharma PLC – POLB 001 LPS Challenge Trial Paper Published January 28, 2026 – Posted in: Poolbeg Pharma (POLB)

28 January 2026- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the publication of a peer-reviewed paper from the POLB 001 LPS human challenge trial in Frontiers in Immunology. Key conclusions from the paper include:   ·          POLB 001 significantly reduced key inflammatory biomarkers and immune cell recruitment following LPS challenge in healthy volunteers ·          POLB 001 was safe and well tolerated across…

Continue reading